277 related articles for article (PubMed ID: 38668051)
1. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.
Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP; Germing U; Malcovati L
Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
[TBL] [Abstract][Full Text] [Related]
3. The International Consensus Classification of myelodysplastic syndromes and related entities.
Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
[TBL] [Abstract][Full Text] [Related]
5. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Capodanno I; Neri A; Morabito F; Vigna E; Gentile M
Eur J Haematol; 2024 Jun; 112(6):860-869. PubMed ID: 38294126
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Zavras PD; Sinanidis I; Tsakiroglou P; Karantanos T
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902450
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
9. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
[TBL] [Abstract][Full Text] [Related]
11. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
14. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
15. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
[TBL] [Abstract][Full Text] [Related]
16. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
17. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic abnormalities in myelodysplastic syndrome: an overview.
Kawankar N; Vundinti BR
Hematology; 2011 May; 16(3):131-8. PubMed ID: 21669051
[TBL] [Abstract][Full Text] [Related]
19. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
[TBL] [Abstract][Full Text] [Related]
20. Impact of the International Consensus Classification of myelodysplastic syndromes.
Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]